Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov:212:111144.
doi: 10.1016/j.radonc.2025.111144. Epub 2025 Sep 13.

Association of artificial intelligence-screened interstitial lung disease with radiation pneumonitis in locally advanced non-small cell lung cancer

Affiliations

Association of artificial intelligence-screened interstitial lung disease with radiation pneumonitis in locally advanced non-small cell lung cancer

Hannah Bacon et al. Radiother Oncol. 2025 Nov.

Abstract

Purpose: Interstitial lung disease (ILD) has been correlated with an increased risk for radiation pneumonitis (RP) following lung SBRT, but the degree to which locally advanced NSCLC (LA-NSCLC) patients are affected has yet to be quantified. An algorithm to identify patients at high risk for RP may help clinicians mitigate risk.

Methods: All LA-NSCLC patients treated with definitive radiotherapy at our institution from 2006 to 2021 were retrospectively assessed. A convolutional neural network was previously developed to identify patients with radiographic ILD using planning computed tomography (CT) images. All screen-positive (AI-ILD + ) patients were reviewed by a thoracic radiologist to identify true radiographic ILD (r-ILD). The association between the algorithm output, clinical and dosimetric variables, and the outcomes of grade ≥3 RP and mortality were assessed using univariate (UVA) and multivariable (MVA) logistic regression, and Kaplan-Meier survival analysis.

Results: 698 patients were included in the analysis. Grade (G) 0-5 RP was reported in 51 %, 27 %, 17 %, 4.4 %, 0.14 % and 0.57 % of patients, respectively. Overall, 23 % of patients were classified as AI-ILD+. On MVA, only AI-ILD status (OR 2.15, p = 0.03) and AI-ILD score (OR 35.27, p < 0.01) were significant predictors of G3+RP. Median OS was 3.6 years in AI-ILD- patients and 2.3 years in AI-ILD+patients (NS). Patients with r-ILD had significantly higher rates of severe toxicities, with G3+RP 25 % and G5 RP 7 %. R-ILD was associated with an increased risk for G3+RP on MVA (OR 5.42, p < 0.01).

Conclusion: Our AI-ILD algorithm detects patients with significantly increased risk for G3+RP.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BH Lok reports grants (not related to the current project) from AstraZeneca, Pfizer, National Institute of Health/National Cancer Institute, Canadian Institutes of Health Research, and Terry Fox Research Institute. BH Lok reports payment or honoraria (not related to the current project) from AstraZeneca and Daiichi-Sankyo. All remaining authors have declared no other conflicts of interest.

MeSH terms

LinkOut - more resources